Showing results (3631-3640 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|June 8, 2004
Flt3 receptor tyrosine kinase as a drug target in leukemiaDirk Schmidt-Arras, Joachim Schwäble, Frank-D Böhmer, et al.Current Pharmaceutical Design|June 8, 2004
MEK inhibitors: a therapeutic approach to targeting the Ras-MAP kinase pathway in tumorsJudith S Sebolt-LeopoldCurrent Pharmaceutical Design|June 8, 2004
Monitoring therapy with gene expression profiling reveals physiological differences in drug actionS Wölfl, A Burchert, T C KrollCurrent Pharmaceutical Design|June 8, 2004
Tumor intracellular redox status and drug resistance--serendipity or a causal relationship?Shazib Pervaiz, Marie-Veronique ClementCurrent Pharmaceutical Design|June 8, 2004
Rational drug design of multifunctional phosphoramidate substituted nucleoside analogsT K Venkatachalam, P A Goodman, S Qazi, et al.Current Pharmaceutical Design|June 8, 2004
The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapyChristopher S NavaraCurrent Pharmaceutical Design|June 8, 2004
Src: regulation, role in human carcinogenesis and pharmacological inhibitorsA Y Tsygankov, S K ShoreCurrent Pharmaceutical Design|March 22, 2005
Amino thiols, detoxification and oxidative stress in pre-eclampsia and other disorders of pregnancyM T M Raijmakers, W H M Peters, E A P Steegers, et al.Current Pharmaceutical Design|March 22, 2005
ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activityLance C Bridges, Ron D BowditchCurrent Pharmaceutical Design|June 25, 2005
Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancerF Paulhe, S Manenti, L Ysebaert, et al.Pageof 1,008